Moody Aldrich Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Moody Aldrich Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,243	Closed	-$1.31M	–	184
2023 Q1	$1.31M	Sell	12,243 -440	-3%	-$50.6K	0.27%	110
2022 Q4	$1.4M	Buy	+12,683	New	+$822K	0.28%	104

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Moody Aldrich Partners's RXDX Position: Q2 2023 in Review

Moody Aldrich Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 12,243 shares — an estimated $1.31M sold.

Moody Aldrich Partners first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Moody Aldrich Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Moody Aldrich Partners sold 12,243 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.31M.
Moody Aldrich Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Moody Aldrich Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $1.4M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Moody Aldrich Partners's 13F filing for Q2 2023, filed 28 Jul 2023.